Development of nanotheranostics against metastatic breast cancer - A focus on the biology & mechanistic approaches

Biotechnology Advances

Volumn 33, Issue 8, 2015, Pages 1897-1911

  Subramanian, Anuradha ^a   Manigandan, Amrutha ^a   P R , Sivashankari ^a   Sethuraman, Swaminathan ^a  

^a SASTRA UNIVERSITY   (India)

Author keywords

Breast cancer; Metastasis; Nanoparticles; SPIONs; Theranostics

Indexed keywords

BIOLOGY; CELLS; DISEASE CONTROL; DISEASES; NANOPARTICLES; PATHOLOGY; TUMORS;

BREAST CANCER; CIRCULATING TUMOR CELLS; CLINICAL MANAGEMENT; METASTASIS; MICROSCOPIC LEVELS; SPIONS; THERANOSTICS; TREATMENT RESPONSE;

DIAGNOSIS;

NANOMATERIAL;

BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; THERANOSTIC NANOMEDICINE; TUMOR EMBOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS; NANOSTRUCTURES; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; THERANOSTIC NANOMEDICINE;

BIOLOGY; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DRUG DEVELOPMENT; MORTALITY; NANOPARTICLE; TUMOR;

EID: 84949024116     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2015.10.002     Document Type: Review

References (149)

1. American Cancer Society Breast Cancer Facts & Figures 2013-2014 2013, Cancer Society, Atlanta.
2. Bang S., Jang S.I., Lee S.Y., Baek Y.Y., Yun J., Oh S.J., Lee C.W., Jo E.A., Na K., Yang S., Lee D.H., Lee D.K. Molecular mechanism of local drug delivery with paclitaxel-eluting membranes in biliary and pancreatic cancer: new application for an old drug. Gastroenterol. Res. Pract. 2014.
3. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G., Giavazzi R., Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 1996, 2:1843-1849.
4. Ben-Haim S., Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin. Nucl. Med. 2009, 39:408-415.
5. Bhattacharya S., Ahir M., Patra P., Mukherjee S., Ghosh S., Mazumdar M., Chattopadhyay S., Das T., Chattopadhyay D., Adhikary A. PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a. Biomaterials 2015, 51:91-107.
6. Binder S. Evolution of taxanes in the treatment of metastatic breast cancer. Clin. J. Oncol. Nurs. 2013, 17:9-14.
7. Blum J.L., Savin M.A., Edelman G., Pippen J.E., Robert N.J., Geister B.V., Kirby R.L., Clawson A., O'Shaughnessy J.A. Phase II Study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin. Breast Cancer 2007, 7:850-856.
8. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313.
9. Bonezzi K., Belotti D., North B.J., Ghilardi C., Borsotti P., Resovi A., Ubezio P., Riva A., Giavazzi R., Verdin E., Taraboletti G. Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia 2012, 14:846-854.
10. Branca R.T., Cleveland Z.I., Fubara B., Kumar C.S., Maronpot R.R., Leuschner C., Warren W.S., Driehuys B. Molecular MRI for sensitive and specific detection of lung metastases. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3693-3697.
11. Bravo Marques J.M. Treatment of brain metastases in patients with HER2+ breast cancer. Adv. Ther. 2009, 26:S18-S26.
12. Bray F., McCarron P., Parkin D.M. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004, 6:229-239.
13. Cao H., Zhang Z., Zhao S., He X., Yu H., Yin Q., Zhang Z., Gu W., Chen L., Li Y. Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression. J. Control. Release 2015, 205:162-171.
14. Carneiro M.L., Peixoto R.C., Joanitti G.A., Oliveira R.G., Telles L.A., Miranda-Vilela A.L., Bocca A.L., Vianna L.M., da Silva I.C., de Souza A.R., Lacava Z.G., Báo S.N. Antitumor effect and toxicity of free rhodium (II) citrate and rhodium (II) citrate-loaded maghemite nanoparticles in mice bearing breast cancer. J. Nanobiotechnol. 2013, 11:4.
15. Chapman S., Dobrovolskaia M., Farahani K., Goodwin A., Joshi A., Lee H., Meade T., Pomper M., Ptak K., Rao J., Singh R., Sridhar S., Stern S., Wang A., Weaver J.B., Woloschak G., Yang L. Nanoparticles for cancer imaging: the good, the bad, and the promise. Nano Today 2013, 8:454-460.
16. Chen Y.C., Sosnoski D.M., Mastro A.M. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010, 12:215.
17. Cheng S.H., Chen M.C., Lee C.H., Souris J.S., Tseng F.G., Mou C.Y., Yang C.S., Chen C.T., Lo L.W. Tri-functionalization of mesoporous silica nanoparticles for comprehensive cancer theranostics-the trio of imaging, targeting and therapy. J. Mater. Chem. 2010, 20:6149-6157.
18. Choi M.R., Bardhan R., Stanton-Maxey K.J., Badve S., Nakshatri H., Stantz K.M., Cao N., Halas N.J., Clare S.E. Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnol. 2012, 3:47-54.
19. Choi K.Y., Liu G., Lee S., Chen X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 2012, 4:330-342.
20. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007, 8:235-244.
21. Conlin A.K., Seidman A.D., Bach A., Lake D., Dickler M., D'Andrea G., Traina T., Danso M., Brufsky A.M., Saleh M., Clawson A., Hudis C.A. Phase II Trial of weekly nanoparticle albumin bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressingmetastatic breast cancer. Clin. Breast Cancer 2010, 10:281-287.
22. Dave B., Mittal V., Tan N.M., Chang J.C. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012, 14:202.
23. Del Barco S., Colomer R., Calvo L., Tusquets I., Adrover E., Sánchez P., Rifà J., De la Haba J., Virizuela J.A. Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. Breast Cancer Res. Treat. 2009, 116:351-358.
24. Deng X., Cao M., Zhang J., Hu K., Yin Z., Zhou Z., Xiao X., Yang Y., Sheng W., Wu Y., Zeng Y. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 2014, 35:4333-4344.
25. Diamond J.R., Finlayson C.A., Borges V.F. Hepatic complications of breast cancer. Lancet Oncol. 2009, 10:615-621.
26. Downs-Holmes C., Silverman P. Breast cancer: overview and updates. Nurse Pract. 2011, 36(12):20-26.
27. Drasin D.J., Robin T.P., Ford H.L. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res. 2011, 13:226.
28. Drbohlavova J., Chomoucka J., Adam V., Ryvolova M., Eckschlager T., Hubalek J., Kizek R. Nanocarriers for anticancer drugs - new trends in nanomedicine. Curr. Drug Metab. 2013, 14:547-564.
29. Eichler A.F., Loeffler J.S. Multidisciplinary management of brain metastases. Oncologist 2007, 12:884-898.
30. Elazar V., Adwan H., Bäuerle T., Rohekar K., Golomb G., Berger M.R. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein anti-senses in rats with breast cancer bone metastasis. Int. J. Cancer 2010, 126:1749-1760.
31. Ferber S., Baabur-Cohen H., Blau R., Epshtein Y., Kisin-Finfer E., Redy O., Shabat D., Satchi-Fainaro R. Polymeric nanotheranostics for real-time non-invasive optical imaging of breast cancer progression and drug release. Cancer Lett. 2014, 352:81-89.
32. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
33. Filyak Y., Filyak O., Souchelnytskyi S., Stoika R. Doxorubicin inhibits TGF-βsignaling in human lung carcinoma A549 cells. Eur. J. Pharmacol. 2008, 590:67-73.
34. Finlay J., Roberts C.M., Lowe G., Loeza J., Rossi J.J., Glackin C.A. RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis. BioMed Res. Int. 2015, 2015:382745.
35. Foroni C., Broggini M., Generali D., Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat. Rev. 2012, 38:689-697.
36. Friedl P., Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res. 2008, 68:7247-7249.
37. Galanzha E.I., Shashkov E.V., Kelly T., Kim J.W., Yang L., Zharov V.P. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat. Nanotechnol. 2009, 4:855-860.
38. Gandhi S., Sethuraman S., Krishnan U.M. Synthesis, characterization and biocompatibility evaluation of iron oxide incorporated magnetic mesoporous silica. Dalton Trans. 2012, 41:12530-12537.
39. Gandhi S., Venkatesh S., Sharma U., Jagannathan N.R., Sethuraman S., Krishnan U.M. Superparamagnetic nanosystems based on iron oxide nanoparticles & mesoporous silica: synthesis & evaluation of their magnetic, relaxometric and biocompatability properties. J. Mater. Chem. 2011, 21:15698-15707.
40. Ghoneum A., Zhu H., Woo J., Zabinyakov N., Sharma S., Gimzewski J.K. Biophysical and morphological effects of nanodiamond/nanoplatinum solution (DPV576) on metastatic murine breast cancer cells in vitro. Nanotechnology 2014, 25:465101.
41. Ghosh S.K., Uchida M., Yoo B., Ross A.W., Gendler S.J., Gong J., Moore A., Medarova Z. Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model. Int. J. Cancer 2013, 132:1860-1867.
42. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
43. Granchi C., Funaioli T., Erler J.T., Giaccia A.J., Macchia M., Minutolo F. Bioreductively activated lysyl oxidase inhibitors against hypoxic tumours. ChemMedChem 2009, 4:1590-1594.
44. Guo L., Yan D.D., Yang D., Li Y., Wang X., Zalewski O., Yan B., Lu W. Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles. ACS Nano 2014, 8:5670-5681.
45. Guo C., Yu H., Feng B., Gao W., Yan M., Zhang Z., Li Y., Liu S. Highly efficient ablation of metastatic breast cancer using ammonium-tungsten-bronze nanocube as a novel 1064 nm-laser-driven photothermal agent. Biomaterials 2015, 52:407-416.
46. Hambrecht A., Jandial R., Neman J. Emerging role of brain metastases in the prognosis of breast cancer patients. Breast cancer (dove Med press): targets and. Therapy 2011, 3:79-91.
47. Harada T., Tanigawa N., Matsuki M., Nohara T., Narabayashi I. Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur. J. Radiol. 2007, 63:401-407.
48. Hegde G.V., de la Cruz C., Eastham-Anderson J., Zheng Y., Sweet-Cordero E.A., Jackson E.L. Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity. PLoS One 2012, 7:e45647.
49. Helle M., Cassette E., Bezdetnaya L., Pons T., Leroux A., Plénat F., Guillemin F., Dubertret B., Marchal F. Visualisation of sentinel lymph node with indium-based near infrared emitting quantum dots in a murine metastatic breast cancer model. PLoS One 2012, 7.
50. Hellebust A., Richards-Kortum R. Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics. Nanomedicine (London) 2012, 7:429-445.
51. Hinton C.V., Avraham S., Avraham H.K. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin. Exp. Metastasis 2010, 27:97-105.
52. Hollis C.P., Weiss H.L., Evers B.M., Gemeinhart R.A., Li T. In vivo investigation of hybrid paclitaxel nanocrystals with dual fluorescent probes for cancer theranostics. Pharm. Res. 2014, 31:1450-1459.
53. Huang L., Chen S., Yao L., Liu G., Wu J., Shao Z. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. Int. J. Nanomedicine 2015, 10:1969-1975.
54. Husseini G.A., Pitt W.G. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv. Drug Deliv. Rev. 2008, 60:1137-1152.
55. Irvin W., Muss H.B., Mayer D.K. Symptom management in metastatic breast cancer. Oncologist 2011, 16:1203-1214.
56. Jaidev L.R., Bhavsar D.V., Sharma U., Jagannathan N.R., Krishnan U.M., Sethuraman S. Engineered multifunctional nanomaterials for multimodal imaging of retinoblastoma cells in vitro. J. Biomater. Sci. Polym. Ed. 2014, 25:1093-1109.
57. Käkönen S.M., Mundy G.R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003, 97:834-839.
58. Kanapathipillai M., Mammoto A., Mammoto T., Kang J.H., Jiang E., Ghosh K., Korin N., Gibbs A., Mannix R., Ingber D.E. Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix. Nano Lett. 2012, 12:3213-3217.
59. Kelkar S.S., Reineke T.M. Theranostics: combining imaging and therapy. Bioconjug. Chem. 2011, 22:1879-1903.
60. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., Nielsen T.O., Gelmon K. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 2010, 28:3271-3277.
61. Khokhar A. Breast cancer in India: where do we stand and where do we go?. Pac. J. Cancer Prev. 2012, 13:4861-4866.
62. Kievit F.M., Stephen Z.R., Veiseh O., Arami H., Wang T., Lai V.P., Park J.O., Ellenbogen R.G., Disis M.L., Zhang M. Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano 2012, 6:2591-2601.
63. Kojima C., Suehiro T., Watanabe K., Ogawa M., Fukuhara A., Nishisaka E., Harada A., Kono K., Inui T., Magata Y. Doxorubicin-conjugated dendrimer/collagen hybrid gels for metastasis-associated drug delivery systems. Acta Biomater. 2013, 9:5673-5680.
64. Kosaka N., Bernardo M., Mitsunaga M., Choyke P.L., Kobayashi H. MR and optical imaging of early micrometastases in lymph nodes: triple labeling with nano-sized agents yielding distinct signals. Contrast Media Mol. Imaging 2012, 7:247-253.
65. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 2008, 99:392-397.
66. Lau D.H., Xue L., Young L.J., Burke P.A., Cheung A.T. Paclitaxel (taxol): an inhibitor of angiogenesis in a highly vascularised transgenic breast cancer. Cancer Biother. Radiopharm. 1999, 14:31-36.
67. Lermite E., Marzano E., Chéreau E., Rouzier R., Pessaux P. Surgical resection of liver metastases from breast cancer. Surg. Oncol. 2010, 19:e79-e84.
68. Leuschner C., Kumar C.S., Hansel W., Soboyejo W., Zhou J., Hormes J. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res. Treat. 2006, 99:163-176.
69. Li J., Cai P., Shalviri A., Henderson J.T., He C., Foltz W.D., Prasad P., Brodersen P.M., Chen Y., DaCosta R., Rauth A.M., Wu X.Y. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. ACS Nano 2014, 8:9925-9940.
70. Li Y., Jin M., Shao S., Huang W., Yang F., Chen W., Zhang S., Xia G., Gao Z. Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model. BMC Cancer 2014, 14:329.
71. Li M., Tang Z., Zhang Y., Lv S., Li Q., Chen X. Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis. Acta Biomater. 2015, 18:132-143.
72. Liu R., Gilmore D.M., Zubris K.A., Xu X., Catalano P.J., Padera R.F., Grinstaff M.W., Colson Y.L. Colson. Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles. Biomaterials 2013, 34:1810-1819.
73. Liu X.L., Peng C.W., Chen C., Yang X.Q., Hu M.B., Xia H.S., Liu S.P., Pang D.W., Li Y. Quantum dots-based double-color imaging of HER2 positive breast cancer invasion. Biochem. Biophys. Res. Commun. 2011, 409:577-582.
74. Liu P., Qin L., Wang Q., Sun Y., Zhu M., Shen M., Duan Y. CRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer. Biomaterials 2012, 33:6739-6747.
75. Lluch A., Alvarez I., Muñoz M., Seguí M.Á., Tusquets I., García-Estévez L. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. Crit. Rev. Oncol. Hematol. 2014, 89:62-72.
76. Lorusso G., Rüegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin. Cancer Biol. 2012, 22:226-233.
77. Lu X., Kang Y. Organotropism of breast cancer metastasis. J. Mammary Gland Biol. Neoplasia 2007, 12:153-162.
78. Ma P., Rahima Benhabbour S., Feng L., Mumper R.J. 2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer. Cancer Lett. 2013, 334:253-262.
79. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
80. Marrache S., Choi J.H., Tundup S., Zaver D., Harn D.A., Dhar S. Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer. Integr. Biol. (Camb) 2013, 5:215-223.
81. Meng H., Xing G., Blanco E., Song Y., Zhao L., Sun B., Li X., Wang P.C., Korotcov A., Li W., Liang X.J., Chen C., Yuan H., Zhao F., Chen Z., Sun T., Chai Z., Ferrari M., Zhao Y. Gadolinium metallofullerenol nanoparticles inhibit cancer metastasis through matrix metalloproteinase inhibition: imprisoning instead of poisoning cancer cells. Nanomedicine 2012, 8:136-146.
82. Montero A.J., Adams B., Diaz-Montero C.M., Glück S. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert. Rev. Clin. Pharmacol. 2011, 4:329-334.
83. Motomura K., Ishitobi M., Komoike Y., Koyama H., Noguchi A., Sumino H., Kumatani Y., Inaji H., Horinouchi T., Nakanishi K. SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer. Ann. Surg. Oncol. 2011, 18:3422-3429.
84. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
85. Mura S., Couvreur P. Nanotheranostics for personalized medicine. Adv. Drug Deliv. Rev. 2012, 64:1394-1416.
86. Murakami M., Ernsting M.J., Undzys E., Holwell N., Foltz W.D., Li S.D. Docetaxel conjugate nanoparticles that target α-smooth muscle actin - expressing stromal cells suppress breast cancer metastasis. Cancer Res. 2013, 73:4862-4871.
87. Na H.B., Lee J.H., An K., Park Y.I., Park M., Lee I.S., Nam D.H., Kim S.T., Kim S.H., Kim S.W., Lim K.H., Kim K.S., Kim S.O., Hyeon T. Development of aT1Contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew. Chem. Int. Ed. Engl. 2007, 119:5493-5497.
88. Nakai G., Matsuki M., Harada T., Tanigawa N., Yamada T., Barentsz J., Narumi Y. Evaluation of axillary lymph nodes by diffusion-weighted MRI using ultrasmall superparamagnetic iron oxide in patients with breast cancer: initial clinical experience. J. Magn. Reson. Imaging 2011, 34:557-562.
89. Nune S.K., Gunda P., Thallapally P.K., Lin Y.Y., Forrest M.L., Berkland C.J. Nanoparticles for biomedical imaging. Expert Opin. Drug Deliv. 2009, 6:1175-1194.
90. Palange A.L., Di Mascolo D., Carallo C., Gnasso A., Decuzzi P. Lipid-polymer nanoparticles encapsulating curcumin for modulating the vascular deposition of breast cancer cells. Nanomedicine 2014, 10:991-1002.
91. Pan D., Cai X., Yalaz C., Senpan A., Omanakuttan K., Wickline S.A., Wang L.V., Lanza G.M. Photoacoustic sentinel lymph node imaging with self-assembled copper neodecanoate nanoparticles. ACS Nano 2012, 6:1260-1267.
92. Parker B., Sukumar S. Distant metastasis in breast cancer: molecular mechanisms and a search for therapeutic targets. Cancer Biol. Ther. 2003, 2:14-21.
93. Patil S.D., Rhodes D.G., Burgess D.J. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. 2005, 7:E61-E77.
94. Peiris P.M., Toy R., Doolittle E., Pansky J., Abramowski A., Tam M., Vicente P., Tran E., Hayden E., Camann A., Mayer A., Erokwu B.O., Berman Z., Wilson D., Baskaran H., Flask C.A., Keri R.A., Karathanasis E. Imaging metastasis using an integrin-targeting chain-shaped nanoparticle. ACS Nano 2012, 6:8783-8795.
95. Peng J., Qi T., Liao J., Chu B., Yang Q., Qu Y., Li W., Li H., Luo F., Qian Z. Mesoporous magnetic gold "nanoclusters" as theranostic carrier for chemo-photothermal Co-therapy of breast cancer. Theranostics 2014, 4:678-692.
96. Pereira E.R., Jones D., Jung K., Padera T.P. The lymph node microenvironment and its role in the progression of metastatic cancer. Semin. Cell Dev. Biol. 2015, 38:98-105.
97. Pourtau L., Oliveira H., Thevenot J., Wan Y., Brisson A.R., Sandre O., Miraux S., Thiaudiere E., Lecommandoux S. Antibody-functionalized magnetic polymersomes: in vivo targeting and imaging of bone metastases using high resolution MRI. Adv. Healthcare Mater. 2013, 2:1420-1424.
98. Repesh L.A., Drake S.R., Warner M.C., Downing S.W., Jyring R., Seftor E.A., Hendrix M.J., McCarthy J.B. Adriamycin-induced inhibition of melanoma cell invasion is correlated with decreases in tumor cell motility and increases in focal contact formation. Clin. Exp. Metastasis 1993, 11:91-102.
99. Riahi R., Gogoi P., Sepehri S., Zhou Y., Handique K., Godsey J., Wang Y. A novel microchannel-based device to capture and analyze circulating tumor cells (CTCs) of breast cancer. Int. J. Oncol. 2014, 6:1870-1878.
100. Rimassa L., Carnaghi C., Garassino I., Salvini P., Ginanni V., Gullo G., Morenghi E., Santoro A. Unexpected low efficacy of stealth liposomal doxorubicin (caelyx) and vinorelbine in metastatic breast cancer. Breast Cancer Res. Treat. 2003, 77:185-188.
101. Rose A.A., Siegel P.M. Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol. 2010, 6:55-74.
102. Sahani D.V., Kalva S.P. Imaging the liver. Oncologist 2004, 9:385-397.
103. Sanna V., Pala N., Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int. J. Nanomedicine 2014, 9:467-483.
104. Schnitt S.J. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod. Pathol. 2010, 23:S60-S64.
105. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., Jacks T., Anderson D.G. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 2012, 12:50.
106. Scully O.J., Bay B.-H., Yip G., Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics 2012, 9:311-320.
107. Shah B.P., Pasquale N., De G., Tan T., Ma J., Lee K.B. Core-shell nanoparticle-based peptide therapeutics and combined hyperthermia for enhanced cancer cell apoptosis. ACS Nano 2014, 8:9379-9387.
108. Shen J., Sun H., Xu P., Yin Q., Zhang Z., Wang S., Yu H., Li Y. Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. Biomaterials 2013, 34:1581-1590.
109. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65:5-29.
110. Smirnov D.A., Zweitzig D.R., Foulk B.W., Miller M.C., Doyle G.V., Pienta K.J., Meropol N.J., Weiner L.M., Cohen S.J., Moreno J.G., Connelly M.C., Terstappen L.W.M.M., O'Hara S.M. Global gene expression profiling of circulating tumor cells. Cancer Res. 2005, 65:4993-4997.
111. Smith L., Kuncic Z., Ostrikov K., Kumar S. Nanoparticles in cancer imaging and therapy. J. Nanomater. 2012, 10.1155/2012/891318.
112. Sodipo B.K., Aziz A.A. A sonochemical approach to the direct surface functionalization of superparamagnetic iron oxide nanoparticles with (3-aminopropyl) triethoxysilane. Beilstein J. Nanotechnol. 2014, 5:1472-1476.
113. Song W.J., Du J.Z., Sun T.M., Zhang P.Z., Wang J. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small 2010, 6:239-246.
114. Stickeler E., Klar M., Watermann D., Geibel A., Földi M., Hasenburg A., Gitsch G. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer:a multicenter phase II trial. Breast Cancer Res. Treat. 2009, 117:591-598.
115. Sun S., Tang L., Zhang J., Lv F., Wang Z., Wang L., Zhang Q., Zheng C., Qiu L., Jia Z., Lu Y., Liu G., Shao Z., Wang B., Hu X. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. Int. J. Nanomedicine 2014, 9:1443-1452.
116. Tang L., Yang X., Dobrucki L.W., Chaudhury I., Yin Q., Yao C., Lezmi S., Helferich W.G., Fan T.M., Cheng J. Aptamer-functionalized, ultra-small, monodisperse silica nanoconjugates for targeted dual-modal imaging of lymph nodes with metastatic tumors. Angew. Chem. Int. Ed. Engl. 2012, 124:12893-12898.
117. Tang S., Yin Q., Su J., Sun H., Meng Q., Chen Y., Chen L., Huang Y., Gu W., Xu M., Yu H., Zhang Z., Li Y. Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (b-amino ester) nanoparticles co-delivering two siRNA and paclitaxel. Biomaterials 2015, 48:1-15.
118. Tazhibi M., Feizi A. Awareness levels about breast cancer risk factors, early warning signs, and screening and therapeutic approaches among Iranian adult women: a large population based study using latent class analysis. BioMed Res. Int. 2014, 10.1155/2014/306352.
119. Thamake S.I., Raut S.L., Gryczynski Z., Ranjan A.P., Vishwanatha J.K. Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials 2012, 33:7164-7173.
120. Theek B., Rizzo L.Y., Ehling J., Kiessling F., Lammers T. The theranostic path to personalized nanomedicine. Clin. Transl. Imaging 2014, 2:66-76.
121. Thibaudeau L., Quent V.M., Holzapfel B.M., Taubenberger A.V., Straub M., Hutmacher D.W. Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies. Cancer Metastasis Rev. 2014, 33:721-735.
122. Tseng Y.C., Xu Z., Guley K., Yuan H., Huang L. Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. Biomaterials 2014, 35:4688-4698.
123. Tuxen M.K., Cold S., Tange U.B., Balslev E., Nielsen D.L. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer. Acta Oncol. 2014, 53:1440-1445.
124. Varkouhi A.K., Verheul R.J., Schiffelers R.M., Lammers T., Storm G., Hennink W.E. Gene silencing activity of siRNA polyplexes based on thiolated N,N,N-trimethylated CHITOSAN. Bioconjug. Chem. 2010, 21:2339-2346.
125. Ventola C.L. The nanomedicine revolution. Part 1: emerging concepts. P T 2012, 37:512-525.
126. Wadasadawala T., Gupta S., Bagul V., Patil N. Brain metastases from breast cancer: management approach. J. Cancer Res. Ther. 2007, 3:157-165.
127. Wan X., Zheng X., Pang X., Zhang Z., Jing T., Xu W., Zhang Q. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. Int. J. Pharm. 2015, 484:16-28.
128. Wang Y., Zhou B.P. Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin. J. Cancer 2011, 30:603-611.
129. Wang Y., Gao S., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 2006, 5:791-796.
130. Wang D., Xu Z., Yu H., Chen X., Feng B., Cui Z., Lin B., Yin Q., Zhang Z., Chen C., Wang J., Zhang W., Li Y. Treatment of metastatic breast cancer by combination of chemotherapy and photothermal ablation using doxorubicin-loaded DNA wrapped gold nanorods. Biomaterials 2014, 35:8374-8384.
131. Wang Z., Yu Y., Dai W., Cui J., Wu H., Yuan L., Zhang H., Wang X., Wang J., Zhang X., Zhang Q. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth. Biomaterials 2013, 34:756-764.
132. Weigelt B., Peterse J.L., van't Veer L.J. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 2005, 5:591-602.
133. Wilczewska A.Z., Niemirowicz K., Markiewicz K.H., Car H. Nanoparticles as drug delivery systems. Pharmacol. Rep. 2012, 64:1020-1037.
134. Wilson C., Holen I., Coleman R.E. Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat. Rev. 2012, 38:877-889.
135. Wolff A.C., Wang M., Li H., Pins M.R., Pretorius F.J., Rowland K.M., Sparano J.A., Davidson N.E. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: eastern cooperative oncology group trial E3198. Breast Cancer Res. Treat. 2010, 121:111-120.
136. Wu N.Y., Cheng H.C., Ko J.S., Cheng Y.C., Lin P.W., Lin W.C., Chang C.Y., Liou D.M. Magnetic resonance imaging for lung cancer detection: experience in a population of more than 10,000 healthy individuals. BMC Cancer 2011, 11:242.
137. Xu P., Yin Q., Shen J., Chen L., Yu H., Zhang Z., Li Y. Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS. Int. J. Pharm. 2013, 454:21-30.
138. Yallapu M.M., Othman S.F., Curtis E.T., Bauer N.A., Chauhan N., Kumar D., Jaggi M., Chauhan S.C. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int. J. Nanomedicine 2012, 7:1761-1779.
139. Yang X.Q., Chen C., Peng C.W., Hou J.X., Liu S.P., Qi C.B., Gong Y.P., Zhu X.B., Pang D.W., Li Y. Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays. Int. J. Nanomedicine 2011, 6:2265-2273.
140. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
141. Yang L., Peng X.H., Wang Y.A., Wang X., Cao Z., Ni C., Karna P., Zhang X., Wood W.C., Gao X., Nie S., Mao H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res. 2009, 15:4722-4732.
142. Yao H., Veine D.M., Fay K.S., Staszewski E.D., Zeng Z.Z., Livant D.L. The PHSCN dendrimer as a more potent inhibitor of human breast cancer cell invasion, extravasation, and lung colony formation. Breast Cancer Res. Treat. 2011, 125:363-375.
143. Yigit M.V., Ghosh S.K., Kumar M., Petkova V., Kavishwar A., Moore A., Medarova Z. Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis. Oncogene 2013, 32:1530-1538.
144. Yoneda T., Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun. 2005, 328:679-687.
145. Zhang Y., Ma B., Fan Q. Mechanisms of breast cancer bone metastasis. Cancer Lett. 2010, 292:1-7.
146. Zhang W., Meng J., Ji Y., Li X., Kong H., Wu X., Xu H. Inhibiting metastasis of breast cancer cellsin vitrousing gold nanorod-siRNA delivery system. Nanoscale 2011, 3:3923-3932.
147. Zhang F., Zhu L., Huang X., Niu G., Chen X. Differentiation of reactive and tumor metastatic lymph nodes with diffusion-weighted and SPIO enhanced MRI. Mol. Imaging Biol. 2013, 15:40-47.
148. Zharov V.P., Galanzha E.I. Circulating tumor cell detection and capture by photoacoustic flow cytometry in vivo and ex vivo. Cancers 2013, 5:1691-1738.
149. Zubris K.A., Liu R., Colby A., Schulz M.D., Colson Y.L., Grinstaff M.W. In vitro activity of paclitaxel-loaded polymeric expansile nanoparticles in breast cancer cells. Biomacromolecules 2013, 14:2074-2082.